760 related articles for article (PubMed ID: 24690280)
1. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
Moragas M; Soler M; Riera E; García JR
Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
[TBL] [Abstract][Full Text] [Related]
2. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
3. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.
Damle NA; Bal C; Bandopadhyaya GP; Kumar L; Kumar P; Malhotra A; Lata S
Jpn J Radiol; 2013 Apr; 31(4):262-9. PubMed ID: 23377765
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors.
Al-Bulushi NK; Abouzied ME
Nucl Med Commun; 2016 Jun; 37(6):583-8. PubMed ID: 26813992
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
6. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of two-phase
Seo JH; Lee SM; Yu SN; Lee JW; Lee JE
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):238-242. PubMed ID: 30665751
[TBL] [Abstract][Full Text] [Related]
8. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
10. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
11. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG PET/CT versus bone scintigraphy in the follow-up of gastric cancer.
Sollini M; Calabrese L; Zangheri B; Erba PA; Gramaglia A; Gasparini M
Rev Esp Med Nucl Imagen Mol; 2016; 35(2):121-3. PubMed ID: 26653282
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
16. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
Lee JW; Lee SM; Lee HS; Kim YH; Bae WK
Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551
[TBL] [Abstract][Full Text] [Related]
17. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV
Azad GK; Cousin F; Siddique M; Taylor B; Goh V; Cook GJR
Mol Imaging Biol; 2019 Aug; 21(4):781-789. PubMed ID: 30250989
[TBL] [Abstract][Full Text] [Related]
18. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT.
Krüger S; Buck AK; Mottaghy FM; Hasenkamp E; Pauls S; Schumann C; Wibmer T; Merk T; Hombach V; Reske SN
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1807-12. PubMed ID: 19504092
[TBL] [Abstract][Full Text] [Related]
19. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
Sahin E; Zincirkeser S; Akcan AB; Elboga U
J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
[TBL] [Abstract][Full Text] [Related]
20. The value of quantitative analysis in
Lapa P; Marques M; Costa G; Lima JP
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):78-84. PubMed ID: 27793635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]